Promotion of Cell Death in Cisplatin-Resistant Ovarian Cancer Cells through KDM1B-DCLRE1B Modulation

Ovarian cancer is the gynecological malignancy with the poorest prognosis, in part due to its high incidence of recurrence. Platinum agents are widely used as a first-line treatment against ovarian cancer. Recurrent tumors, however, frequently demonstrate acquired chemo-resistance to platinum agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yeon Kyu, Lim, Jinyeong, Yoon, So Young, Joo, Jong Cheon, Park, Soo Jung, Park, Yoon Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566920/
https://www.ncbi.nlm.nih.gov/pubmed/31108893
http://dx.doi.org/10.3390/ijms20102443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566920/
https://www.ncbi.nlm.nih.gov/pubmed/31108893
http://dx.doi.org/10.3390/ijms20102443

Ejemplares similares